Showing 3911-3920 of 4165 results for "".
- Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpointshttps://modernod.com/news/ocuphires-vega-1-phase-2-trial-in-presbyopia-meets-primary-and-secondary-endpoints/2479332/Ocuphire Pharma announced that the VEGA-1 phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move in
- Gyroscope Announces Research Collaboration with CMRI to Develop Gene Therapy Capsidshttps://modernod.com/news/gyroscope-announces-research-collaboration-with-cmri-to-develop-gene-therapy-capsids/2479315/Gyroscope Therapeutics announced the company has entered a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies. A team of researchers from CMRI
- Implandata’s Receives CE Mark for the EYEMATE-SC Biosensor for Remote Glaucoma Carehttps://modernod.com/news/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/2479310/Implandata Ophthalmic Products announced that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the EYEMATE system for digitally enabled remote glaucoma monitoring and management. The patented EYEMATE system is the world’s only clinically-validated pro
- Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-safety-results-from-cohort-1-of-oasis-phase-1-2a-trial-of-cls-ax-for-the-treatment-of-wet-amd/2479292/Clearside Biomedical announced positive safety results from Cohort 1 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in six patients (n=6) with neovascular age-rel
- EyeYon Medical Receives CE Mark for its EndoArt Implant to Treat Chronic Corneal Edemahttps://modernod.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/2479277/EyeYon Medical announced that it has received CE Mark for its EndoArt after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. EyeYon says the EndoArt is the world’s first and only synthetic implant that replaces the human endothelium that the human
- Noveome Biotherapeutics Announces Preliminary Results of its Phase 1 Trial Evaluating Intranasal Delivery of ST266 In Glaucoma Suspect Patientshttps://modernod.com/news/noveome-biotherapeutics-announces-preliminary-results-of-its-phase-1-trial-evaluating-intranasal-delivery-of-st266-in-glaucoma-suspect-patients/2479275/Noveome Biotherapeutics announced preliminary results of a phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally in glaucoma suspect patients. The trial was conducted at the University of Pennsylvania by Ahmara Ross, MD, PhD, and Kenneth Shindler, MD, PhD,
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicoxs-completes-pre-defined-enrollment-of-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479250/Nicox announced that more than 200 patients, the pre-defined target, have been randomized in the NCX 4251 Mississippi phase 2b blepharitis clinical trial. Topline results are expected to be announced during September 2021. “Blepharitis is a highly prevalent eye condition with frequent exac
- GenSight Biologics Announces Case Report Showing Visual Recovery after GS030 Optogenetic Treatmenthttps://modernod.com/news/gensight-biologics-announces-nature-medicine-case-report-showing-visual-recovery-after-gs030-optogenetic-treatment/2479243/GenSight Biologics announced that the journal Nature Medicine has published the first case report of partial recovery of visual function in a blind patient with late-stage retinitis pigmentosa (RP). The subject is a participant in the ongoing PIONEER phase 1/2 clinical trial of GenSight
- Study Examines ImprimisRx’s Proprietary Klarity-C for Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/multicenter-retrospective-study-examines-imprimisrxs-proprietary-klarity-c-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2479218/ImprimisRx, a wholly owned subsidiary of Harrow Health, announced that a study of its Klarity-C Drops (cyclosporine 0.1% ophthalmic emulsion PF) has been published in the peer-reviewed journal, Clinical Ophthalmology.1 Klarity-C is a compounded preservative-free cyclosporine e